Progressive & Dynamic —
Our agile and highly experienced teams are ready to adapt to changing situations at a moment’s notice. As a company, we are proud to say we are small enough to care but big enough to make a difference.
Unique and Collaborative —
ADVANZ PHARMA is committed to investing in the growth of our people and rewarding and recognising the contribution they make while providing a unique culture that includes a collaborative and flexible working environment – our people are encouraged to work up to 3 days a week remotely, helping them operate at the very best of their ability while ensuring work life balance.
Ready to join?
Help people lead better lives with medicines, that without our focus, may not be available.
Our Values
Our values reflect who we are and what we stand for. Having a purpose, goal and values would mean nothing if we didn’t have the people to bring them to life, to share the journey and vision of building a company we believe in. From London to Mumbai, Helsingborg to Sydney and Canada to Chicago, resilience and common values have united ADVANZ PHARMA, regardless of geography or remote working situation.
Entrepreneurship
- Own the solution and take accountability for results
- Focus on what drives impact for patients, customers, and the enterprise
Speed
- Bias for action and fast decision making
- Focus on high-priority tasks and rapid implementation
Integrity
- Come together – open, collaborative, honest, and respectful cooperation
- Act with social responsibility and in-line with legal, regulatory, and industry standards
Our Commitment —
-
Ethical Standards
To serve the needs of patients and healthcare providers across the world by operating at high ethical standards.Learn more -
Accreditation
We were re-accredited to BS 10500 in 2017 and in November 2018 we became one of the first pharma companies in the world to achieve ISO37001 accreditation for our comprehensiveLearn more -
Safe and Effective
We are committed to providing medicines safely and effectively, all to the highest quality standards.Learn more -
Open, Transparent and Collaborative
We aspire to be open, transparent, and collaborative in all our relationships and believe in the power of partnership to build trust and inspire better solutions.Learn more
Our Portfolio
Portfolio of specialty, hospital, and rare disease medicines
ADVANZ PHARMA’s product portfolio and pipeline comprises innovative medicines, specialty generics & biosimilars, and originator brands. Our products cover a broad range of therapeutic areas, including hepatology, gastroenterology, anti-infectives, critical care, endocrinology, oncology, CNS, and, more broadly, rare diseases.
Within innovative medicines, one of our key products is Ocaliva® (obeticholic acid), for which we have the commercial rights for Europe and all other countries outside the US. Ocaliva® is an innovative rare disease medicine for the treatment of Primary Biliary Cholangitis (PBC). PBC is a rare liver disease that is caused by an autoimmune reaction, which damages bile ducts in the liver. Bile ducts are tube-like structures that carry bile from the liver to the intestine to help digest. In addition, our pipeline of innovative medicines includes, for example, the commercial rights for prospective treatments for the rare diseases Galactosemia and SORD Deficiency, as well as for innovative anti-infectives.
Within specialty generics & biosimilars, one of our key products is Mytolac®/Myrelez® (lanreotide). We have been the first company to launch a generic lanreotide in Europe. Lanreotide is a synthetic version of the natural hormone somatostatin and is used for the treatment of neuroendocrine tumours (NETs) and carcinoid syndrome. Another key product in our portfolio is Palmeux® (paliperidone 1-month long-acting injection) for the treatment of schizophrenia. Our broad specialty generics portfolio covers multiple therapeutic areas and ensures patient access to affordable, high-quality medicines. In addition, our product pipeline comprises rights to various specialty generics & biosimilars in therapeutic areas like oncology, endocrinology, respiratory, and anti-infectives.
Within originator brands, we are commercialising global or regional brands acquired from originator pharma companies. These include, for example, Zonegran® (zonisamide) for the treatment of epilepsy, Resolor® (prucalopride succinate) for the symptomatic treatment of chronic constipation, and various other products across a broad range of indications.
Our Commitment
-
Our purpose is to help patients lead healthier, better lives by revitalising and innovating niche established medicines that, without our focus, may otherwise not be available.
But this is not always easy – either because the divestor company has discontinued the manufacture of a medicine and an alternative manufacturer needs to be found or a medicine was originally developed several decades ago which means it can be difficult to manufacture without significant investment to bring it up to date in line with current regulatory requirements.
Our experience of supplying and developing niche established medicines for decades means we have a rich heritage of acquiring and investing in these valuable medicines through targeted development, product in-licensing and acquisition to bring them to more markets or by improving product formulation and strength to optimise treatment so that patients can continue to use them for years to come.
Bringing medicines to a wider market
Over the last 15 years, we have acquired more than 15 legacy brands for our international markets and approx. 10 brands for the US market meaning more patients are able to continue to access them.
Medicines we have revitalized or optimized
Over the last 10 years, we have worked across 20 initiatives to optimise or revitalize medicines to enhance patient care and provide greater choice.
Corporate Governance
ADVANZ PHARMA is committed to conducting its business ethically and in compliance with all applicable laws, regulations, guidelines, and policies. ADVANZ PHARMA has established and implemented a Code of Conduct (the “Code”), which sets forth ADVANZ PHARMA's commitment to ethical business conduct.
-
Compliance Officer
The Compliance Officer is responsible for overseeing the administration and implementation of ADVANZ PHARMA’s compliance program and will report at least quarterly to the Compliance Committee. The Compliance Officer has authority to direct and implement compliance-related changes and to determine the corporate response to compliance-related matters.
-
Compliance Committee
ADVANZ PHARMA has established a Compliance Committee and the committee meets on a quarterly basis. The Compliance Committee is responsible for ensuring the implementation and effectiveness of the Compliance Program, and to provide advice and support to the Compliance Officer.
-
Compliance Policies
ADVANZ PHARMA policies and procedures were developed to ensure that interactions with healthcare professionals are appropriate, ethical, and consistent with applicable laws and standards. ADVANZ PHARMA expects its employees to comply with the compliance program, its Code of Conduct, policies, procedures, and all applicable laws. Employees must annually acknowledge their responsibility and commitment to conduct ADVANZ PHARMA’s business consistent with these standards and to report to real or suspect violations. Employees who violate these standards are subject to appropriate disciplinary action, up to and including termination. ADVANZ PHARMA’s policies prohibit retaliation against any employee for making a good faith report.
-
Communicating Compliance & Policies
ADVANZ PHARMA is committed to an environment in which open communications are encouraged, including questions or concerns about the compliance program. Employees are required to report any activity or individual that is suspect or in violation of the compliance program. Employees may contact direct managers, the Chief Executive Officer, the Chief Financial Officer, the Compliance Officer or the Compliance Committee at compliance@advanzpharma.com or they may use the Compliance Hotline by calling 855-562-5982. The Hotline is available 24 hours a day/7 days a week to allow confidential and anonymous reporting.
-
ADVANZ PHARMA ESG Report
-
Monitoring, Auditing & Investigations
The compliance program includes activities designed to monitor and audit compliance with ADVANZ PHARMA policies and procedures. The Compliance Officer oversees monitoring and auditing through an audit plan, including internal and external auditing activities. The Compliance Officer works with relevant resources to evaluate audit findings and ensure the implementation of any corrective action. The Compliance Officer (or designee) reviews and evaluates concerns to determine the required investigative response.
-
Corrective Action & Discipline
If it is determined that noncompliant conduct has occurred, appropriate parties are responsible for corrective and/or disciplinary actions. ADVANZ PHARMA’s disciplinary actions may include the following: termination; disciplining any involved employee(s); disciplining supervisor for failure to monitor employees appropriately. ADVANZ PHARMA’s corrective and preventative actions may include: revising the compliance program, policies, and/or procedures; revising the role of the Compliance Committee; increased auditing and monitoring; revising the training program.
-
Updating the Compliance programme
As ADVANZ PHARMA evolves as a company and as regulations change, it may amend its compliance program. The Compliance Committee reviews and approves all suggested changes. The Compliance Officer shall be responsible for communicating changes in the compliance program to employees.
-
California Compliance Law Declaration
As part of ADVANZ PHARMA’s continuing commitment to corporate compliance, ADVZ declares that, to the best of its knowledge, and based on a good faith understanding of the statutory requirements of California Health and Safety Code § 119400 and 119402, it has adopted a Comprehensive Compliance Program as mandated by this California law. To the best of our knowledge, as of November 1, 2017, ADVZ believes that it is in compliance with its Comprehensive Compliance Program and its good faith understanding of the requirements of California Health and Safety Code § 119400 and 119402.
Additionally, to comply with California law, ADVZ has established a maximum annual aggregate dollar limit of $1,500 for gifts, promotional materials or activities provided to California health care professionals. This dollar limit represents a spending cap, not a goal or average, and typically the amount spent per physician is anticipated to be substantially less than this maximum amount.
For questions about our Comprehensive Compliance Program or to obtain a copy, please contact us at compliance@advanzpharma.com. -
Advanz Pharma AGM 2019
Our Leadership Team
-
Steffen Wagner —
Chief Executive Officer
-
Andreas Stickler —
Chief Financial Officer
-
Javier Barcelo —
Chief Commercial Officer Europe
-
Karl Belk —
Chief Operations Officer
-
Susanna El-Armale —
Chief Corporate Development Officer
-
Fiona Huzarski —
Chief People Officer
-
Anke Niedernberg —
Chief Transformation Officer
-
Simon Tucker —
Chief Commercial Officer International
-
Nick Warwick —
Chief Medical Officer
-
Eve-Anadel Coronado —
Group General Counsel
Close ×Steffen Wagner —
Chief Executive Officer
Steffen joined ADVANZ PHARMA as CEO in April 2022 and has broad general management experience in international life science businesses. He is a medical doctor by training, has previously held senior roles with STADA, Biogen and within the Novartis Group, and worked as a consultant at McKinsey and Bain. His industry experience covers Biotech, Pharma, MedTech, Biosimilars, Generics, and OTC. He lead businesses in context of large European-based multinational Pharmaco, US-based Biotech, and Private Equity portfolio companies and likes to work with strong teams to drive business growth, transformation, and M&A
Close ×Andreas Stickler —
Chief Financial Officer
Andreas Stickler joined ADVANZ PHARMA from Merck Healthcare, part of Merck KGaA, where he was Chief Financial Officer and also served as Global Head of M&A and Business Development for many years. Before that, he held several finance roles at Hoechst/Aventis and Degussa/Evonik in Treasury, Capital Markets and Risk Management and brings a wealth of Finance, Healthcare and M&A expertise to the team.
Close ×Javier Barcelo —
Chief Commercial Officer Europe
Javier has over 30 years’ experience within the pharmaceutical industry spending time in both ‘big’ pharma and within the biotech space. He was most recently the Region VP for Iberia, France, and ROW at Intercept. Previously he worked at Human Genome Sciences, Vertex, and Biogen. Javier has deep and diverse experience across multiple therapeutic areas in both innovative and mature products. Javier holds bachelor’s degree in law and has complemented his education with an Executive MBA at the Instituto de Empresa Business School.
Close ×Karl Belk —
Chief Operations Officer
Karl has more than 30 years of experience in manufacturing, packaging, supply chain and distribution, and 20 years in senior management and leadership positions including his role as Operations Director for Teva. As Chief Operations Officer for ADVANZ PHARMA, Karl leads all operations functions globally, including scientific affairs (medical, regulatory and quality), supply (supply chain and supplier alliance management), new product introductions and technical operations.
Close ×Susanna El-Armale —
Chief Corporate Development Officer
Susanna brings over 15 years of leadership experience in the pharmaceutical industry, specialising in leading buy and build initiatives, transformational turnarounds, organic pipeline development, and devising and implementing strategic plans for geographic expansion. Susanna is responsible for M&A, BD&L and Data and Market Intelligence at ADVANZ and will drive the development and execution of the company’s growth plans.
Prior to joining ADVANZ, she played a pivotal role in the establishment and growth of PE-backed Theramex, where she was part of the core management team who carved-out more than 20 assets across multiple geographies to create a stand-alone specialty pharmaceutical company.
Close ×Fiona Huzarski —
Chief People Officer
Fiona Huzarski has worked for over 20 years as a senior HR professional, 15 years within the Pharmaceuticals industry. As Vice President of Global HR, she is responsible for leading the Global HR function and setting the People Strategy to create an inclusive, flexible and collaborative environment where all employees can grow and develop in support of the company’s long-term goals.
Prior to joining ADVANZ PHARMA as Vice President of Global HR in August 2019, she was Global HR Director at Britannia Pharmaceuticals, part of the STADA group. Her career started in the Management Consulting sector before joining GSK’s Global Recruitment Team and working for 10 years at UCB in various Senior HR roles, supporting the Commercial, R&D and Technical Operations functions in both UK & Ireland and across Europe. She is a Fellow of the Chartered Institute of Personnel & Development (CIPD) and holds a Post graduate Diploma in Human Resource Management from Thames Valley University.
Close ×Anke Niedernberg —
Chief Transformation Officer
Anke joined ADVANZ PHARMA in October 2021. She brings over 15 years’ experience from strategic and operational management positions in the pharmaceutical and consulting industry and will be essential in leading the company’s transformation journey as it continues its expansion focusing on commercialising complex medicines in Europe to even better serve our patients and customers.
A pharmacist by training, she holds a PhD in molecular biology. Prior to joining ADVANZ PHARMA, Anke worked at McKinsey, HgCapital and most recently, held various global roles across Strategy, Launch and Portfolio Management as well building and driving the local German ehealth Strategy at Sandoz.
Close ×Simon Tucker —
Chief Commercial Officer International
Simon has worked in the Pharma industry for over 24 years initially joining Pfizer in the UK. Simon has had over 20 years’ experience within the ADVANZ family of companies and has focused the majority of his career Internationally being responsible for both direct and indirect business across Europe, North America, MENA, Latin America and Asia whilst living and working in the USA, UK and Jersey. Simon holds an International Business degree and has over the years built up a huge network of International pharma partners across the world many of which continue to successfully distribute and promote the wide portfolio of ADVANZ products.
Close ×Nick Warwick —
Chief Medical Officer
Dr Nick Warwick has over 30 years of experience both in the pharmaceutical industry and as a medical doctor. Nick trained as a medical Doctor at Charing Cross Hospital Medical School in London, now part of the Imperial College group, and spent 10 years in clinical medicine rotating through disciplines including emergency medicine, rheumatology and rehabilitation, dermatology, ear nose and throat surgery, obstetrics and gynaecology, and primary care, before joining the Pharmaceutical Industry in 1997 as Medical Adviser for Abbott. In the following 24 years, Nick held senior country level, regional and global leadership roles within Medical Affairs and Clinical Development (Abbott and Abbvie) and was Chief Medical Officer for Sandoz (2014-2019). Nick joined ADVANZ PHARMA as Chief Medical Officer in June 2020.
Close ×Eve-Anadel Coronado —
Group General Counsel
Before she was appointed as Group General Counsel for ADVANZ PHARMA in May 2022, Eve-Anadel Coronado joined Concordia International in 2018 and supported the M&A and BD&L teams. Eve has broad legal experience in international life sciences and held roles at Hikma Pharmaceuticals, Pharmascience and IQVIA (formerly IMS Health) where she worked in the R&D, Scientific Affairs, Business Development, M&A, Global Operations, Supply Chain, Commercial, Marketing and Sales teams. Before venturing into life sciences, Eve also worked for law firms in Paris and Montreal. Eve speaks French, Spanish and English fluently.
-
Steffen Wagner —
-
Andreas Stickler —
-
Raj Shah —
-
Rainer Lenhard —
Close ×Steffen Wagner —
Steffen joined ADVANZ PHARMA as CEO in April 2022 and has broad general management experience in international life science businesses. He is a medical doctor by training, has previously held senior roles with STADA, Biogen and within the Novartis Group, and worked as a consultant at McKinsey and Bain. His industry experience covers Biotech, Pharma, MedTech, Biosimilars, Generics, and OTC. He led businesses such as large European-based multinational Pharmaco, US-based Biotech, and Private Equity portfolio companies and likes to work with strong teams to drive business growth, transformation, and M&A.
Close ×Andreas Stickler —
Andreas Stickler joined ADVANZ PHARMA from Merck Healthcare, part of Merck KGaA, where he was Chief Financial Officer and also served as Global Head of M&A and Business Development for many years. Before that, he held several finance roles at Hoechst/Aventis and Degussa/Evonik in Treasury, Capital Markets and Risk Management and brings a wealth of Finance, Healthcare and M&A expertise to the team.
Close ×Raj Shah —
Joined in May 2015. Raj has over 25 years of experience in the healthcare industry. He is Head of the Healthcare sector team and he is the responsible advisor for Nordic Capital investments in the sector. Raj holds several non-executive positions including the boards of ERT, ArisGlobal, Alloheim and Royal Brompton and Harefield Hospitals Charity. Prior to joining, Raj’s healthcare experience spans both working as a practitioner, having initially qualified and practiced as a cardiac surgeon at Oxford, through to extensive transactional experience gained as Co-Head of Goldman Sachs healthcare investment banking practice where he advised private equity and corporate clients. Raj holds degrees in medicine and surgery from Imperial College, London as well as being Fellow of the Royal College of Surgeons and an MBA from London Business School.
Close ×Rainer Lenhard —
Rainer joined in June 2019, as a Partner and Co-Head of the DACH region with focus on Nordic Capital’s core sectors Healthcare, Technology & Payments and Financial Services. Rainer joined from Goldman Sachs where he was Managing Director focusing on European healthcare companies. He is of German origin and started his career at McKinsey & Company, working across various industries in the DACH region. Rainer studied business administration at WHU Koblenz and holds a doctorate/PhD from Friedrich-Alexander-Universität Erlangen-Nürnberg.
Our Locations —
-
London —
UK (Corporate Headquarters)
-
Sydney —
Australia
-
Toronto —
Canada
-
Bielefeld & Munich —
Germany
-
Mumbai —
India
-
Dublin —
Ireland
-
Milan —
Italy
-
Madrid —
Spain
-
Helsingborg —
Sweden
-
Chicago —
USA
Close ×London —
UK (Corporate Headquarters)
Capital House, 85 King Willian Street, London, EC4N 7BL
Close ×Sydney —
Australia
Level 9, 76 Berry Street, North Sydney NSW 2060
Close ×Toronto —
Canada
Close ×Bielefeld & Munich —
Germany
Herforder Str. 69, 33602 Bielefeld
Rosenheimer Str. 52
81669 München
+49 89 4111 124 11
Close ×Mumbai —
India
Level 5, Tower-II, Phase-II Raiaskaran Tech Park, Andheri Kurla Road, Andheri (East), Mumbai, 400 072
Direct: +91 22 6678 4444
Fax: +91 22 6677 1262
Close ×Dublin —
Ireland
17 Northwood House, Northwood, Santry, Dublin 9, D09 V504
Ormond Building, 31-36 Ormond Quay Upper, Dublin 7, Dublin, Dublin, Republic of Ireland
+353 1800 902 105
Close ×Milan —
Italy
Via Giosue Carducci 24
20123 Milano, Italy
+39 02 66661030
Close ×Madrid —
Spain
Paseo de la Castellana, 135
7º piso
28046 Madrid, Spain
T: +34 912 975 506
Close ×Helsingborg —
Sweden
Bergaliden 11, 252 23 Helsingborg
Close ×Chicago —
USA
2801 Lakeside Drive, Suite 210, Bannockburn, IL 60015